Nagai N, Oshita T, Fujii T, Kioka H, Katsube Y, Ohama K
Department of Obstetrics and Gynecology, Hiroshima University Faculty of Medicine, Minami-ku, Hiroshima 734-8551, Japan.
Oncol Rep. 2000 May-Jun;7(3):551-9. doi: 10.3892/or.7.3.551.
For the purpose of identifying prognostic factors for pretreated uterine cancer, DNA ploidy, proliferative index (P.I.) and epidermal growth factor receptor (EGFR) expression were analyzed in a large prospective series of 76 cervical cancer and 64 endometrial cancer patients observed for 5 years or more (median 76 months). The frequency of aneuploid cells was 62.0% (44/71) in cervical cancer and 16.7% (10/60) in endometrial cancer. There was no association between DNA ploidy and the clinicopathological findings without clinical stage, in which aneuploid cervical and endometrial cancers were significantly more common among advanced tumors (cervical: p<0. 05, endometrial: p<0.01). The P.I. was significantly higher in the patients with aneuploid tumors (cervical: p<0.05, endometrial p<0. 01). EGFR expression was detected in 56.6% (30/53) in cervical cancer and 59.6% (34/57) in endometrial cancer, and the mean EGFR level was 17.8+/-37.7 and 9.5+/-42.5 fmol/mg. protein, respectively. There was no correlation between EGFR expression and DNA ploidy, P.I. and clinicopathological findings analyzed. Five-year survival rate in patients with aneuploid tumors tended to have a worse outcome in cervical cancer cases (p=0.1003, log-rank test), and was significantly worse in endometrial cancer (p=0.0048, log-rank test). No significant relationship was noted between P.I., EGFR expression and 5-year survival. Cox multivariate analysis showed that DNA ploidy, P.I., and EGFR expression are not association with the risk of death. Our data showed neither DNA ploidy, P.I. nor EGFR expression were independent prognostic factors for pretreated uterine cancer.
为了确定经治疗的子宫癌的预后因素，我们对76例宫颈癌和64例子宫内膜癌患者进行了一项大型前瞻性研究，观察时间为5年或更长时间（中位时间76个月），分析了DNA倍体、增殖指数（P.I.）和表皮生长因子受体（EGFR）表达情况。宫颈癌中非整倍体细胞的频率为62.0%（44/71），子宫内膜癌为16.7%（10/60）。在不考虑临床分期的情况下，DNA倍体与临床病理结果之间无关联，其中非整倍体宫颈癌和子宫内膜癌在晚期肿瘤中更为常见（宫颈癌：p<0.05，子宫内膜癌：p<0.01）。非整倍体肿瘤患者的P.I.显著更高（宫颈癌：p<0.05，子宫内膜癌：p<0.01）。宫颈癌中EGFR表达的检测率为56.6%（30/53），子宫内膜癌为59.6%（34/57），EGFR平均水平分别为17.8±37.7和9.5±42.5 fmol/mg蛋白质。EGFR表达与DNA倍体、P.I.及分析的临床病理结果之间无相关性。非整倍体肿瘤患者的5年生存率在宫颈癌病例中倾向于较差（p=0.1003，对数秩检验），在子宫内膜癌中显著较差（p=0.0048，对数秩检验）。未发现P.I.、EGFR表达与5年生存率之间存在显著关系。Cox多因素分析表明，DNA倍体、P.I.和EGFR表达与死亡风险无关。我们的数据表明，DNA倍体、P.I.和EGFR表达均不是经治疗的子宫癌的独立预后因素。
